Ellen S. Hong

434 total citations
11 papers, 219 citations indexed

About

Ellen S. Hong is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Ellen S. Hong has authored 11 papers receiving a total of 219 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 3 papers in Cancer Research and 2 papers in Genetics. Recurrent topics in Ellen S. Hong's work include Glioma Diagnosis and Treatment (2 papers), Cancer Genomics and Diagnostics (2 papers) and Protein Degradation and Inhibitors (2 papers). Ellen S. Hong is often cited by papers focused on Glioma Diagnosis and Treatment (2 papers), Cancer Genomics and Diagnostics (2 papers) and Protein Degradation and Inhibitors (2 papers). Ellen S. Hong collaborates with scholars based in United States and Denmark. Ellen S. Hong's co-authors include Chand Khanna, Ling Ren, Arnulfo Mendoza, Michael M. Lizardo, James J. Morrow, Charles Halsey, Peter C. Scacheri, Sandra Burkett, Tanasa S. Osborne and Samuel Q. Li and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Ellen S. Hong

9 papers receiving 216 citations

Peers

Ellen S. Hong
Paola Francica Switzerland
Anthony M. Boutelle United States
Allyson E. Koyen United States
Paola Francica Switzerland
Ellen S. Hong
Citations per year, relative to Ellen S. Hong Ellen S. Hong (= 1×) peers Paola Francica

Countries citing papers authored by Ellen S. Hong

Since Specialization
Citations

This map shows the geographic impact of Ellen S. Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen S. Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen S. Hong more than expected).

Fields of papers citing papers by Ellen S. Hong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen S. Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen S. Hong. The network helps show where Ellen S. Hong may publish in the future.

Co-authorship network of co-authors of Ellen S. Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen S. Hong. A scholar is included among the top collaborators of Ellen S. Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen S. Hong. Ellen S. Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Mulkearns-Hubert, Erin E., Ellen S. Hong, Kristen Kay, et al.. (2025). Connexin 43 drives glioblastoma cancer stem cell phenotypes through a WNK lysine-deficient protein kinase 1-c-MYC signaling axis. Cell Reports. 44(9). 116303–116303. 1 indexed citations
2.
Hong, Ellen S., Sabrina Wang, Juyeun Lee, et al.. (2024). miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma. Neuro-Oncology Advances. 6(1). vdae183–vdae183.
3.
Lee, Juyeun, et al.. (2023). 1022 Sex-biased T cell exhaustion drives differential immune responses in glioblastoma. SHILAP Revista de lepidopterología. A1130–A1130.
4.
Troike, Katie, Sabrina Wang, Daniel J. Silver, et al.. (2023). Homeostatic iron regulatory protein drives glioblastoma growth via tumor cell-intrinsic and sex-specific responses. Neuro-Oncology Advances. 6(1). 1 indexed citations
5.
Pontius, William, Ellen S. Hong, Zachary Faber, et al.. (2023). Temporal chromatin accessibility changes define transcriptional states essential for osteosarcoma metastasis. Nature Communications. 14(1). 7209–7209. 5 indexed citations
6.
Hung, Stevephen, Alina Saiakhova, Zachary Faber, et al.. (2019). Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomes. eLife. 8. 16 indexed citations
7.
Bayles, Ian, Małgorzata Krajewska, William Pontius, et al.. (2019). Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. Journal of Clinical Investigation. 129(10). 4377–4392. 34 indexed citations
8.
Zhao, Lili, et al.. (2018). 400 Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma. Journal of Investigative Dermatology. 138(5). S68–S68. 1 indexed citations
9.
Ren, Ling, Ellen S. Hong, Arnulfo Mendoza, et al.. (2017). Metabolomics uncovers a link between inositol metabolism and osteosarcoma metastasis. Oncotarget. 8(24). 38541–38553. 38 indexed citations
10.
Lizardo, Michael M., James J. Morrow, Tyler E. Miller, et al.. (2016). Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression. Neoplasia. 18(11). 699–710. 43 indexed citations
11.
Ren, Ling, Arnulfo Mendoza, Jack Zhu, et al.. (2015). Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. Oncotarget. 6(30). 29469–29481. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026